Lv2
140 积分 2024-06-04 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed
1个月前
已完结
The rediscovery of platinum-based cancer therapy
1个月前
已完结
Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
1个月前
已完结
LUNG CANCER IN THE 19TH CENTURY
2个月前
已关闭
Detection failure rate of chest radiography for the identification of nursing and healthcare-associated pneumonia
2个月前
已关闭
Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
2个月前
已完结
Aspiration pneumonia and pneumonitis: a spectrum of infectious/noninfectious diseases affecting the lung
2个月前
已完结
The landscape of EGFR pathways and personalized management of non-small-cell lung cancer
4个月前
已完结
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
4个月前
已完结
皖公网安备34019202002308
